O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-3.5%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$4.82B
AUM Growth
+$4.82B
(-12%)
Cap. Flow
-$176M
Cap. Flow
% of AUM
-3.65%
Top 10 Holdings %
Top 10 Hldgs %
44.7%
Holding
132
New
19
Increased
23
Reduced
22
Closed
17
Top Buys
| 1 |
UPB
Upstream Bio, Inc. Common Stock
UPB
|
$93.6M |
| 2 |
Neurocrine Biosciences
NBIX
|
$86.8M |
| 3 |
Edwards Lifesciences
EW
|
$84.8M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$38.9M |
| 5 |
Cytokinetics
CYTK
|
$38.4M |
Top Sells
| 1 |
Amgen
AMGN
|
$81.3M |
| 2 |
Elevance Health
ELV
|
$55.2M |
| 3 |
Merck
MRK
|
$48.4M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$47.5M |
| 5 |
Evolent Health
EVH
|
$47.1M |
Sector Composition
| 1 | Healthcare | 98.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Vertex Pharmaceuticals
VRTX
$100B
| $60.8M | 1.25% | 151,000 | – | – |
|
|
THRD
27
DELISTED
Third Harmonic Bio
THRD
| $59.5M | 1.22% | 5,779,071 | – | – |
|
28
Crinetics Pharmaceuticals
CRNX
$2.92B
| $51.1M | 1.05% | 999,000 -51,055 | -5% | -$2.61M |
|
29
Universal Health Services
UHS
$11.6B
| $48.3M | 0.99% | 269,300 +113,300 | +73% | +$20.3M |
|
30
SI-BONE Inc
SIBN
$719M
| $48.3M | 0.99% | 3,442,853 +137,052 | +4% | +$1.92M |
|
|
SWTX
31
DELISTED
SpringWorks Therapeutics
SWTX
| $45.3M | 0.93% | 1,255,031 -135,600 | -10% | -$4.9M |
|
32
Thermo Fisher Scientific
TMO
$186B
| $43.9M | 0.9% | 84,400 | – | – |
|
33
Terns Pharmaceuticals
TERN
$609M
| $41.9M | 0.86% | 7,562,971 | – | – |
|
34
CG Oncology
CGON
$2.04B
| $41M | 0.84% | 1,431,114 +740,000 | +107% | +$21.2M |
|
35
Janux Therapeutics
JANX
$1.37B
| $40.6M | 0.84% | 758,566 -500,000 | -40% | -$26.8M |
|
36
Exact Sciences
EXAS
$8.98B
| $38.2M | 0.79% | 679,816 | – | – |
|
37
Neuropace
NPCE
$303M
| $38.1M | 0.78% | 3,406,335 | – | – |
|
38
Xenon Pharmaceuticals
XENE
$2.98B
| $37.2M | 0.76% | 947,877 +36,457 | +4% | +$1.43M |
|
39
Corvus Pharmaceuticals
CRVS
$428M
| $37.1M | 0.76% | 6,943,654 | – | – |
|
40
SPDR S&P Biotech ETF
XBI
$5.07B
| $33.5M | 0.69% | +372,000 | New | +$33.5M |
|
41
Compass Therapeutics
CMPX
$483M
| $32.4M | 0.67% | 22,362,850 | – | – |
|
42
Xtant Medical Holdings
XTNT
$83.3M
| $32.4M | 0.67% | 73,114,592 | – | – |
|
43
Avidity Biosciences
RNA
$5.99B
| $32.4M | 0.67% | 1,112,886 +68,081 | +7% | +$1.98M |
|
44
Vera Therapeutics
VERA
$1.38B
| $31.4M | 0.65% | 742,572 +66,700 | +10% | +$2.82M |
|
45
Dyne Therapeutics
DYN
$1.92B
| $28.9M | 0.59% | 1,227,080 +518,680 | +73% | +$12.2M |
|
46
Cullinan Oncology
CGEM
$445M
| $23.7M | 0.49% | 1,942,555 +872,500 | +82% | +$10.6M |
|
47
Vir Biotechnology
VIR
$686M
| $23.6M | 0.49% | 3,218,617 -354,383 | -10% | -$2.6M |
|
48
Gilead Sciences
GILD
$140B
| $22.7M | 0.47% | 245,600 +93,900 | +62% | +$8.67M |
|
49
Rhythm Pharmaceuticals
RYTM
$6.85B
| $22.4M | 0.46% | 400,000 -35,900 | -8% | -$2.01M |
|
50
Immatics
IMTX
$619M
| $22M | 0.45% | 3,087,462 +1,081,081 | +54% | +$7.69M |
|